Skip to main content
SpringerLink
Log in

Viral clearance during the manufacture of urokinase from human urine

  • Published:
Biotechnology and Bioprocess Engineering Aims and scope Submit manuscript

Abstract

The purpose of the present study was to evaluate the efficacies and mechanisms of the PAB (para-amino benzamidine) affinity column chromatography, virus filtration, pasteurization (60°C heat treatment for 10 h), and lyophilization steps employed in the manufacture of urokinase from human urine with regard to the removal and/or inactivation of human immunodeficiency virus (HIV), bovine viral diarrhoea virus (BVDV), bovine herpes virus (BHV), and murine encephalomyocarditis virus (EMCV). Samples from relevant stages of the production process were spiked with each virus and subjected to scale-down processes mimicking the manufacture of urokinase. Samples were collected at each step, immediately titrated using a 50% tissue culture infectious dose (TCID50), and the virus reduction factors evaluated. PAB chromatography was found to be an effective step for removing BVDV, BHV, and EMCV with log reduction factors of 2.79, 6.50, and 5.96, respectively. HIV, BVDV, BHV, and EMCV were completely removed during the Viresolve NFP filtration step with log reduction factors of ≥6.06, ≥4.60, ≥5.44, and ≥6.87, respectively. Pasteurization was also found to be a robust and effective step in inactivating all the viruses tested, since there were no residual viruses detected after the pasteurization process. The log reduction factors achieved by pasteurization were ≥5.73 for HIV, ≥3.86 for BVDV, ≥6.75 for BHV, and ≥5.92 for EMCV. Lyophilization showed significant efficacy for inactivating BVDV, BHV, and EMCV with log reduction factors of 2.69, 1.37, and 4.70, respectively. These results indicate that the production process for urokinase exhibited a sufficient viral reducing capacity to achieve a high margin of virus safety.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sherry, S. (1987) Thrombolytic therapy in acute myocardial infarction. A perspective. Drugs 33: S1–S12.

    Article  Google Scholar 

  2. Bansal, V. and P. K. Roychoudhury (2006) Production and purification of urokinase: a comprehensive review. Protein Expr. Purif. 45: 1–14.

    Article  CAS  Google Scholar 

  3. Bennion, D. W., L. J. Wright, R. A. Watt, A. A. Whiting, and J. F. Carlquist (1998) Optimal recovery of cytomegalovirus from urine as a function of specimen preparation. Diagn. Microbiol. Infect. Dis. 31: 337–342.

    Article  CAS  Google Scholar 

  4. Coulepis, A. G., S. A. Locarnini, N. I. Lehmann, and I. D. Gust (1980) Detection of hepatitis A virus in the fe-ces of patients with naturally acquired infections. J. In fect. Dis. 141: 151–156.

    CAS  Google Scholar 

  5. Melchers, W. J., R. Schift, E. Stolz, J. Lindeman, and W. G. Quint (1989) Human papillomavirus detection in urine samples from male patients by the polymerase chain reaction. J. Clin. Microbiol. 27: 1711–1714.

    CAS  Google Scholar 

  6. Schalasta, G., M. Eggers, M. Schmid, and G. Enders (2000) Analysis of human cytomegalovirus DNA in urines of newborns and infants by means of a new ultra-rapid real-time PCR-system. J. Clin. Virol. 19: 175–185.

    Article  CAS  Google Scholar 

  7. Kim, I. S., Y. W. Choi, S. R. Lee, Y. Kang, K. M. Lee, D. H. Park, H. S. Woo, and S. Lee (2002) Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine. Biotechnol. Bioprocess Eng. 7: 340–346.

    Article  CAS  Google Scholar 

  8. Kim, I. S., Y. W. Choi, and S. R. Lee (2004) Optimization and validation of a virus filtration process for efficient removal of viruses from urokinase solution pre pared from human urine. J. Microbiol. Biotechnol. 14: 140–147.

    CAS  Google Scholar 

  9. Committee for Proprietary Medicinal Products (CPMP), The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluaation Unit (1996) Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses (CPMP/BWP/268/95).

  10. International Conference on Harmonisation (1998) Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; Availability. Federal Resister 63: 51074–51084.

    Google Scholar 

  11. Kim, I. S., Y. W. Choi, S. R. Lee, and H. M. Sung (2004) Cold ethanol fractionation and heat inactivation of hepatitis A virus during manufacture of albumin from human plasma. Biotechnol. Bioprocess Eng. 9: 65–68.

    Article  CAS  Google Scholar 

  12. Shin, J. S., Y. W. Choi, H. M. Sung, Y. W. Ryu, and I. S. Kim (2006) Enhanced virus safety of a solvent/deter gent-treated antihemophilic factor IX concentrate by dry-heat treatment. Biotechnol. Bioprocess Eng. 11: 19–25.

    Article  CAS  Google Scholar 

  13. Kim, I. S., Y. W. Choi, H. S. Woo, C. E. Chang, and S. Lee (2000) Solvent/detergent inactivation and chromatographic removal of human immunodeficiency virus during the manufacturing of a high purity antihemophilic factor VIII concentrate. J. Microbiol. 38: 187–191.

    CAS  Google Scholar 

  14. Kim, I. S., Y. W. Choi, S. R. Lee, H. S. Woo, and S. Lee (2001) Removal and inactivation of viruses during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. Biotech nol. 11:497–503.

    CAS  Google Scholar 

  15. Kärber, J. (1931) Beitrag zur kollectiven Behandlung pharmakologische Reihenversuche. Arch. Exp. Path. Pharmakol. 162: 480–483.

    Article  Google Scholar 

  16. Aranha, H. (2001) Viral clearance strategies for bio-pharmaceutical safety. Part 1: General considerations. Bio. Pharm. January: 28–35.

    Google Scholar 

  17. Josić, D., P. Schulz, L. Biesert, L. Hoffer, H. Schwinn, M. Kordis-Krapez, and A. Strancar (1997) Issues in the development of medical products based on human plasma J. Chromatogr. B 694: 253–269.

    Article  Google Scholar 

  18. Kim, I. S. (2004) Improvement of parvovirus safety of a human urokinase by a virus filtration process. J. Sci. Inst. Han Nam Univ. 34: 31–40.

    Google Scholar 

  19. Brorson, K., J. Brown, E. Hamilton, and K. E. Stein (2003) Identification of protein A media performance at tributes that can be monitored as surrogates for retrovirus clearance during extended re-use. J. Chromatogr. A 989: 155–163.

    Article  CAS  Google Scholar 

  20. Aranha, H. (2001) Viral clearance strategies for bio-pharmaceutical safety. Part 2: Filtration for viral clearance. Bio. Pharm. February: 32–43.

    Google Scholar 

  21. Schmidt, S., J. Mora, S. Dolan, and J. Kauling (2005) An integrated concept for robust and efficient virus clearance and contaminant removal in biotech processes. BioProcess Int. 3: 26–31.

    Google Scholar 

  22. Remington, K. M., S. R. Trejo, G. Buczynski, H. Li, W. P. Osheroff, J. P. Brown, H. Renfrew, R. Reynolds, and D. Y. Pifat (2004) Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products. Vox. Sang. 87: 10–18.

    Article  CAS  Google Scholar 

  23. Kim, I. S., H. G. Eo, C. E. Chang, and S. Lee (2000) Partitioning and inactivation of viruses by cold ethanol fractionation and pasteurization during manufacture of albumin from human plasma. J. Microbiol. Biotechnol. 10: 858–864. and pasteurization during the manufacture of albumin

    CAS  Google Scholar 

  24. Kim, I. S., H. G. Eo, C. W. Park, C. E. Chang, and S. Lee (2001) Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and immunoglobulins from human plasma. Biotechnol. Bioprocess Eng. 6: 25–30.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Green Cross Corp., Yongin, 449-900, Korea

    Yong Woon Choi

  2. Department of Molecular Science and Technology, College of Engineering, Ajou University, Suwon, 443-749, Korea

    Yong Woon Choi

  3. Department of Biological Sciences, College of Life Science and Nanotechnology, Hannam University, Daejeon, 305-811, Korea

    In Seop Kim

Authors
  1. Yong Woon Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. In Seop Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to In Seop Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Choi, Y.W., Kim, I.S. Viral clearance during the manufacture of urokinase from human urine. Biotechnol Bioproc E 13, 25–32 (2008). https://doi.org/10.1007/s12257-007-0140-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12257-007-0140-7

Keywords

Search

Navigation